Floatz logo

hlx60

Solid Tumor and Lymphoma

Shanghai Henlius Biotechmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Solid Tumor and Lymphoma cohort.

Asset / SponsorPhaseRating
hx111 for
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Phase 1/2NR

Same molecule, other indications

hlx60 is also rated in:

Advanced or Metastatic Solid TumorsDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →